Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) , an emerging pharmaceutical company specializing in the development, manufacturing, and marketing of complex generic and proprietary drugs, represents an attractive investment opportunity against the backdrop of current trends in healthcare and pharmaceuticals.
Amphastar stands out with its focus on complex generics,...
After a deep pullback in August and September, Amphastar is coming back in a big way. Following its early-November earnings report, the stock is up more than 20% in the last few weeks. It has reclaimed all its moving averages and is now consolidation with a pivot at $58.
Volume has dried up nicely during this consolidation which is typically a sign the stock is...
99% forming a cup and handle for $AMPH. Look at the retracement not exceeding 30% and also the long duration to form plus higher volumes at both ends with increasing prices.
MMSI
AMPH
USLM
*Note:
IBD tells "Market in confirmed uptrend(Green sign)"
VIX shows 19.00. VIX<20
Almost no impact of FOMC, CPI, Jobless rate this week.
Notes:
* Strong up trend since late 2021
* Great earnings track record
* Building a base for the past ~4 months
* Building a pivot area around $37.8 for the past three weeks
* Bounced off of the 50 day line with higher than average volume
* Has been using the 50 day line as a dynamic level of support for the past month or so
Technicals:
Sector: Healthcare -...
Buy point: 35.20
Stop: 33.25
Risk:5.5%
Avg Cost: 35.8
I was late to the trade so couldn't fill up my full defensive position. (111.25 Shares, 283.7 USD Risk)
Im now 8% invested on 6 pilot positions.
Amphastar Pharmaceuticals ( NASDAQ:AMPH ) is currently at historical resistance after reaching a new high today at $34.42. It's now above the average analyst target ($28.50 as of 3/7/2022) and insiders have sold $2.2 million in the past 2 months. Earnings on March 10th. The float is near 37 million with a 5.5% short interest. It is at "risk" for a...
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use....
AMPH: Amphastar Pharmaceuticals, Inc.
2020-06-09 06:00:10
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
